PD16-11 EXTERNAL VALIDATION OF THE VENUSS PROGNOSTIC MODEL TO PREDICT DISEASE RECURRENCE AFTER SURGERY FOR NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA: AN ANALYSIS OF A MULTI-INSTITUTIONAL EUROPEAN COHORT

Abstract

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy II (PD16)1 Sep 2021PD16-11 EXTERNAL VALIDATION OF THE VENUSS PROGNOSTIC MODEL TO PREDICT DISEASE RECURRENCE AFTER SURGERY FOR NON-METASTATIC PAPILLARY RENAL CELL CARCINOMA: AN ANALYSIS OF A MULTI-INSTITUTIONAL EUROPEAN COHORT Selcuk Erdem, Umberto Capitanio, Riccardo Campi, Maria Carmen Mir, Eduard Roussel, Nicola Pavan, Onder Kara, Tobias Klatte, Maximilian C. Kriegmair, Enes Degirmenci, Resat Aydin, Andrea Minervini, Sergio Serni, Giacomo Rebez, and Faruk Ozcan Selcuk ErdemSelcuk Erdem More articles by this author , Umberto CapitanioUmberto Capitanio More articles by this author , Riccardo CampiRiccardo Campi More articles by this author , Maria Carmen MirMaria Carmen Mir More articles by this author , Eduard RousselEduard Roussel More articles by this author , Nicola PavanNicola Pavan More articles by this author , Onder KaraOnder Kara More articles by this author , Tobias KlatteTobias Klatte More articles by this author , Maximilian C. KriegmairMaximilian C. Kriegmair More articles by this author , Enes DegirmenciEnes Degirmenci More articles by this author , Resat AydinResat Aydin More articles by this author , Andrea MinerviniAndrea Minervini More articles by this author , Sergio SerniSergio Serni More articles by this author , Giacomo RebezGiacomo Rebez More articles by this author , and Faruk OzcanFaruk Ozcan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001998.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recently, VENUSS (VEnous extension, NUclear grade, Size, Stage) prognostic model was proposed to predict disease recurrence (DR) after curative surgery for non-metastatic papillary renal cell carcinoma (pRCC). The aim of this study was to validate the VENUSS prognostic model in a multi-institutional European cohort. METHODS: A total of 1085 consecutive patients with sporadic, unilateral, non-metastatic and histopathologically confirmed pRCC who underwent partial or radical nephrectomy between 1987 and 2020 were collected from 7 European institutions. External validity of VENUSS prognostic model was tested in 980 patients with follow-up records. The primary outcome of the study was the prediction of DR (defined as any local or distant recurrence) by both the VENUSS score and the corresponding VENUSS risk groups. Recurrence-free survival (RFS) was studied with Kaplan-Meier survival and Cox proportional hazards regression analyses. Discrimination was assessed using the concordance index, and calibration was performed for RFS. RESULTS: The median age was 64 (IQR:55-70) years and 82.6% (n=809) of patients were male. Median VENUSS score was 2 (IQR:0-4), and 62.9% (n=617), 23.9% (n=234) and 13.2% (n=129) of patients were classified into low, intermediate, and high risk in VENUSS model, respectively. At a median follow-up of 48 (IQR:23-88) months, the disease had recurred in 6.6% (n=41), 18.8% (n=44) and 63.8% (n=81) of patients with low, intermediate and high risk group, respectively. The 5-year RFS was 93.8%, 80.7% and 26.7% in low, intermediate and high risk groups, respectively (p<0.001). With each increment in VENUSS score, the risk of DR increased 1.52-fold (95%CI: 1.45-1.60, p<0.001). The discrimination of the VENUSS score for predicting DR was 81.2% (95%CI: 77.5%-84.8%). Compared with the VENUSS low risk group, the risk of DR was increased 2.91-fold (95%CI: 1.90-4.46, p<0.001) in intermediate risk group and 17.9-fold (95% CI 12.25-26.25, p<0.001) in high risk group, while it was 6.07-fold greater in high risk versus intermediate risk group (95% CI 4.17-8.83, p<0.001). Discrimination of the VENUSS group was 78.6% (95% CI 74.8%-82.4%). Both the VENUSS score and risk groups were well calibrated. CONCLUSIONS: In patients with non-metastatic pRCC treated with curatively intended surgery, both the VENUSS score and VENUSS risk groups performed well in predicting DR in this large contemporary multi-institutional European external validation cohort. The VENUSS prognostic model can provide accurate risk prediction for patient counselling, follow-up and patient selection for adjuvant trials. . Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e283-e283 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Selcuk Erdem More articles by this author Umberto Capitanio More articles by this author Riccardo Campi More articles by this author Maria Carmen Mir More articles by this author Eduard Roussel More articles by this author Nicola Pavan More articles by this author Onder Kara More articles by this author Tobias Klatte More articles by this author Maximilian C. Kriegmair More articles by this author Enes Degirmenci More articles by this author Resat Aydin More articles by this author Andrea Minervini More articles by this author Sergio Serni More articles by this author Giacomo Rebez More articles by this author Faruk Ozcan More articles by this author Expand All Advertisement Loading ...